What is the recommended adult dosing of clarithromycin, including adjustments for hepatic impairment and contraindicated drug interactions?

Clarithromycin Adult Dosing

For most adult infections, clarithromycin is dosed at 500 mg twice daily, with dose reduction by 50% required when creatinine clearance falls below 30 mL/min; no specific hepatic dose adjustment is mandated, though caution is warranted in severe hepatic impairment. 1, 2

Standard Dosing Regimens

Immediate-Release Formulation

• Standard dose: 500 mg orally twice daily 1
• Alternative regimen: 250 mg twice daily for less severe infections
• Duration varies by indication (typically 7-14 days)

Extended-Release Formulation

• Dose: 1000 mg (two 500 mg tablets) once daily 2
• Critical requirement: Must be taken with food to maximize bioavailability (30% reduction when taken fasting) 3
• Duration: 7-14 days depending on indication
• Only approved for acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, and community-acquired pneumonia 2

Intermittent Dosing

• Three times weekly: 500 mg three times per week 1
• Used primarily for nontuberculous mycobacterial infections and long-term suppressive therapy

Renal Impairment Adjustments

Reduce dose by 50% when creatinine clearance is <30 mL/min 1, 2

• Example: 250 mg twice daily instead of 500 mg twice daily
• Additional reduction required when co-administered with atazanavir or ritonavir-containing regimens in moderate renal impairment 2
• The parent drug and active metabolite (14-hydroxyclarithromycin) both accumulate with severe renal dysfunction, prolonging elimination half-life 4

Hepatic Impairment Considerations

No specific dose adjustment is mandated for hepatic impairment alone, provided renal function is normal 1, 5

However, important caveats exist:

• Severe hepatic impairment: Exercise caution 1
• Hepatic dysfunction reduces 14-hydroxylation of clarithromycin, decreasing metabolite formation 5
• The decrease in metabolic clearance is partially offset by increased renal clearance of parent drug 5
• For infections where the 14-hydroxy metabolite contributes to antimicrobial activity (e.g., Haemophilus influenzae), reduced efficacy may occur 4, 5

Critical Warning

Clarithromycin is absolutely contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use 2

Contraindicated Drug Interactions

Clarithromycin is a potent CYP3A4 inhibitor, creating multiple absolute contraindications 2:

Cardiovascular Agents

• Cisapride and pimozide: Risk of QT prolongation and ventricular arrhythmias 2
• Ergot alkaloids (ergotamine, dihydroergotamine): Risk of ergot toxicity 2

Lipid-Lowering Agents

• Lovastatin and simvastatin: Risk of rhabdomyolysis 2
• Lomitapide: Severe hepatotoxicity risk 2

Other Contraindications

• Colchicine in patients with renal or hepatic impairment: Risk of colchicine toxicity 2
• Lurasidone: Excessive antipsychotic levels 2

High-Risk Drug Interactions Requiring Caution

Calcium Channel Blockers

• Clarithromycin significantly increases calcium channel blocker levels through CYP3A4 inhibition 6
• Highest risk with nifedipine: 5.33-fold increased odds of acute kidney injury (absolute risk increase 0.63%) 6
• Also increases risk of hypotension and mortality 6
• Consider using azithromycin instead when macrolide therapy is needed in patients on calcium channel blockers

Other CYP3A4 Substrates

• Midazolam: 8-fold increase in oral exposure, 3.2-fold increase in IV exposure 7
• Carbamazepine, cyclosporin, digoxin, theophylline, warfarin: Narrow therapeutic index drugs requiring close monitoring 4

Bidirectional Interactions

• Rifampin/rifabutin: Potent enzyme inducers that significantly decrease clarithromycin levels 4
• Ritonavir and omeprazole: May alter clarithromycin metabolism 4

Special Dosing Considerations

With Rifabutin

When co-administered with rifabutin for mycobacterial infections, reduce rifabutin dose to 150 mg daily (from standard 300 mg) 1

Angiotensin Receptor Blockers

Recent evidence shows clarithromycin increases risk of hyperkalemia (2.05-fold) and acute kidney injury (1.75-fold) when co-prescribed with ARBs, particularly in patients with reduced kidney function 8. Consider azithromycin as alternative.

Critical Safety Warnings

QT Prolongation

Avoid clarithromycin in patients with:

• Known QT prolongation
• Ventricular arrhythmias (including torsades de pointes)
• Hypokalemia or hypomagnesemia
• Significant bradycardia
• Concurrent Class IA or III antiarrhythmics 2

Cardiovascular Mortality Risk

There is evidence of increased all-cause mortality risk one year or more after treatment in patients with coronary artery disease 2. Balance this risk against treatment benefits in this population.

Hepatotoxicity

Discontinue immediately if signs or symptoms of hepatitis develop 2

Practical Algorithm for Prescribing

1. Check renal function: If CrCl <30 mL/min → reduce dose by 50%
2. Review medication list for absolute contraindications (statins, ergots, cisapride, pimozide, colchicine with organ dysfunction)
3. Assess cardiovascular risk: History of QT prolongation, arrhythmias, or coronary artery disease
4. Evaluate high-risk interactions: Calcium channel blockers, ARBs (especially with reduced kidney function), narrow therapeutic index drugs
5. Consider azithromycin alternative if significant drug interaction concerns exist
6. If extended-release formulation used: Ensure patient counseled to take with food